| AASLD

Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice

Read more about Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice

Emina Halilbasic, Romina Fiorotto, Peter Fickert, Hanns‐Ulrich Marschall, Tarek Moustafa, Carlo Spirli, Andrea Fuchsbichler, Judith Gumhold, Dagmar Silbert, Kurt Zatloukal, Cord Langner, Uday Maitra, Helmut Denk, Alan F. Hofmann, Mario Strazzabosco, Michael Trauner – 28 May 2009 – 24‐norursodeoxycholic acid (norUDCA), a side chain–modified ursodeoxycholic acid derivative, has dramatic therapeutic effects in experimental cholestasis and may be a promising agent for the treatment of cholestatic liver diseases.

Living donor liver transplantation using a graft from a donor with situs inversus totalis

Read more about Living donor liver transplantation using a graft from a donor with situs inversus totalis

Jae Min Chun, Gum O. Jung, Gyu Seong Choi, Jae Berm Park, Choon Hyuck David Kwon, Sung‐Joo Kim, Jae‐Won Joh, Suk‐Koo Lee – 28 May 2009

Use of a donor aortic interposition allograft to treat stenosis of the suprahepatic inferior vena cava after liver transplantation

Read more about Use of a donor aortic interposition allograft to treat stenosis of the suprahepatic inferior vena cava after liver transplantation

Kourosh Saeb‐Parsy, Asif Jah, Andrew J. Butler, Stephen Large, Gavin J. Pettigrew, Raaj K. Praseedom, Christopher J. Watson, Neville V. Jamieson – 28 May 2009

Extended criteria donors: The case for liver procurement in donors with a central nervous system malignancy

Read more about Extended criteria donors: The case for liver procurement in donors with a central nervous system malignancy

Olivier Detry – 28 May 2009

Management of adult patients with ascites due to cirrhosis: An update

Read more about Management of adult patients with ascites due to cirrhosis: An update

Bruce A. Runyon – 28 May 2009

Methodological reporting of randomized clinical trials in major gastroenterology and hepatology journals in 2006

Read more about Methodological reporting of randomized clinical trials in major gastroenterology and hepatology journals in 2006

Yu Bai, Jun Gao, Duo‐Wu Zou, Zhao‐Shen Li – 28 May 2009 – To determine the current quality of reporting of randomized clinical trials (RCTs) in the field of gastroenterology and hepatology, we evaluated the methodological reporting of RCTs in six major gastroenterology and hepatology journals.

Long‐term outcome of hepatitis B e antigen–negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time

Read more about Long‐term outcome of hepatitis B e antigen–negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time

Dar‐In Tai, Shi‐Ming Lin, I‐Shyan Sheen, Chia‐Ming Chu, Deng‐Yn Lin, Yun‐Fan Liaw – 28 May 2009 – The baseline alanine aminotransferase (ALT) level was reported to have prognostic value in chronic hepatitis B virus (HBV) infection, during which ALT may change over time. Instead of baseline ALT, this study aimed to study the prognostic value of the height of ALT during the course of chronic HBV infection.

Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis

Read more about Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis

Shannon S. Glaser, Gianfranco Alpini – 28 May 2009

Reply:

Read more about Reply:

Zigmund Luka, M. Luz Martínez‐Chantar, Shelly C. Lu, Conrad Wager, José M. Mato – 28 May 2009

Changes in the serum levels of interleukin‐17/interleukin‐23 during acute rejection in liver transplantation

Read more about Changes in the serum levels of interleukin‐17/interleukin‐23 during acute rejection in liver transplantation

Emilio Fábrega, Marcos López‐Hoyos, David San Segundo, Fernando Casafont, Fernando Pons‐Romero – 28 May 2009 – Interleukin‐23 (IL‐23) and T helper 17 (Th17) cells have been cast as major players in autoimmunity, but their role in transplantation immunity remains to be specified. The aim of our study was to investigate the time course of serum levels of IL‐23 and IL‐17 during hepatic allograft rejection. Serum levels of IL‐23 and IL‐17 were determined in 20 healthy subjects and 50 hepatic transplant recipients.

Subscribe to